In:
International Journal of Cancer, Wiley, Vol. 145, No. 7 ( 2019-10), p. 1935-1945
Abstract:
What's new? Therapy‐induced selection of antigen‐loss variants can result in resistance of pre‐B‐cell acute lymphoblastic leukemia (B‐ALL) to CD19‐directed immunotherapies. To evaluate FLT3 as a target for B‐ALL, here the authors engineered NK‐92 cells to express an FLT3‐specific chimeric antigen receptor (CAR). The CAR NK cells displayed high and selective cytotoxicity against established and primary B‐ALL cells in vitro and markedly reduced leukemia burden in a human B‐ALL xenograft model in vivo . The findings suggest FLT3‐specific CAR NK cells as a promising alternative approach for adoptive immunotherapy of B‐ALL.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8